BioVie Inc. (BIVI)
BIVI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BIVI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001580149 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These circumstances raise substantial doubt on the Company's ability to continue as a going concern." | 10-Q 2026-11-06 |
| Cash and burn | $7.7M cash; operating cash flow -$4.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 10,724,724 (2026-11-05); 7,540,316 a year earlier; 37,742,695 three years earlier. 3y figure adjusted for splits (1-for-100 overall). | Cover page 2026-11-05 |
| Reverse splits, 3 years | 2; latest 1-for-10 on 2025-07-07 | Source 2025-07-07 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 4 424B5 takedowns, 2 at the market | Latest 2026-11-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EisnerAmper LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-08-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $49K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | Not filed | -$5.6M | -$2.9M | $7.7M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q4 2026 2026-06-30 | Not filed | -$5.6M | -$4.1M | $9.0M | No debt tags | Needs four quarters | 10-K 2026-08-13 |
| Q3 2026 2026-03-31 | Not filed | -$5.3M | -$7.4M | $13.1M | No debt tags | Needs four quarters | 10-Q 2026-05-11 |
| Q2 2026 2025-12-31 | Not filed | -$6.1M | -$4.4M | $20.5M | No debt tags | Needs four quarters | 10-Q 2026-05-11 |
| Q1 2026 2025-09-30 | Not filed | -$5.1M | -$3.0M | $25.0M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q4 2025 2025-06-30 | Not filed | -$3.5M | -$5.6M | $17.5M | No debt tags | Needs four quarters | 10-K 2026-08-13 |
| Q3 2025 2025-03-31 | Not filed | -$2.8M | -$1.3M | $23.2M | No debt tags | Needs four quarters | 10-Q 2026-05-11 |
| Q2 2025 2024-12-31 | Not filed | -$7.1M | -$8.6M | $24.4M | No debt tags | Needs four quarters | 10-Q 2026-05-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-05 |
| Latest annual report FORM 10-K FOR PERIOD ENDED JUNE 30, 2026 | 10-K | 2026-08-13 |
| Latest quarterly / interim FORM 10-Q FOR PERIOD ENDING SEPTEMBER 30, 2026 | 10-Q | 2026-11-06 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-09-28 |
Source: SEC EDGAR submissions feed, 512 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.0% |
| 1 month | -5.8% |
| 3 months | -27.6% |
| Year to date | -2.6% |
| 1 year | -24.2% |
| From 52-week high | -50.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| BIVIW | BioVie Inc. Warrant | $0.2500 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DARE | Dare Bioscience Inc. | $0.5842 | -11.13% | $11.5M |
| LSTA | Lisata Therapeutics Inc. | $1.09 | -9.92% | $11.8M |
| ASBP | Aspire-Lakewood Holdings Inc. | $8.06 | -5.29% | $11.3M |
| RADX | Radiopharm Theranostics Limited | $0.7676 | +1.00% | $11.1M |
| QNTM | Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $1.44 | -10.56% | $12.2M |
| PTN | Palatin Technologies Inc. | $6.13 | -1.69% | $10.9M |
| OPTH | Optimi Health Corp. Common Shares | $2.15 | -4.44% | $12.3M |
| HIND | Vyome Holdings Inc. | $1.53 | -3.16% | $10.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier